Ocugen (OCGN) Metrics: History & Chart

Ocugen, Inc.(OCGN)

Biotechnology · Malvern, PA

$1.05+0.01 (+0.96%)

Delayed quote: Oct 6, 2026, 1:30 PM EDT

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

Malvern, PA

116 employees

www.ocugen.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Shankar Musunuri

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	+0.97%
30D Total Return	-23.53%
YTD Total Return	-22.96%
1Y Total Return	-41.24%
3Y Total Return	+151.43%
5Y Total Return	-84.99%
10Y Total Return	-99.46%
15Y Total Return	N/A
20Y Total Return	N/A

2026	-22.96%
2025	+67.70%
2024	+40.00%
2023	-55.77%
2022	-71.43%
2021	+148.63%
2020

CAGR TTM	-41.09%
CAGR 3Y	+35.97%
CAGR 5Y	-31.57%
CAGR 10Y	-40.73%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	186.19
PE Ratio Avg TTM	84.67
PE Ratio Avg 3Y	84.67
Current VS TTM Avg	+119.89%
Current VS 3Y Avg	+119.89%
Current VS 5Y Avg	+119.89%

All Metrics

OCGN Valuation Metrics

OCGN Stock Price Metrics

OCGN Dividend Metrics

OCGN Growth Rate Metrics

OCGN Discounted Cash Flow Metrics

OCGN Returns By Period

OCGN Yearly Returns

OCGN Average Annual Returns By Period (CAGR)

OCGN Revenue Metrics

OCGN PE Ratio Metrics

OCGN PS Ratio Metrics

OCGN PB Ratio Metrics

OCGN Price to Free Cash Flow Ratio Metrics

OCGN Debt to Equity Ratio Metrics

OCGN PEG Ratio Metrics

OCGN FCF Yield

OCGN Earnings Yield

OCGN EBITDA Yield

OCGN OCF Yield

OCGN EV/EBIT Ratio Metrics

OCGN EV/EBITDA Ratio Metrics

OCGN EV/Assets Ratio Metrics

OCGN EV/Sales Ratio Metrics

OCGN Current Ratio Metrics

OCGN Quick Ratio Metrics

OCGN ROIC Metrics

OCGN Return on Assets Metrics

OCGN Return on Equity Metrics

OCGN Net Profit Margin Metrics

OCGN Gross Profit Margin Metrics

OCGN Tax Rate Metrics

PS Ratio	76.91
PS Ratio Avg TTM	95.03
PS Ratio Avg 3Y	62.47
Current VS TTM Avg	-19.07%
Current VS 3Y Avg	+23.12%
Current VS 5Y Avg	+19.63%

PB Ratio	68.45
PB Ratio Avg TTM	110.74
PB Ratio Avg 3Y	38.62
Current VS TTM Avg	-38.19%
Current VS 3Y Avg	+77.23%
Current VS 5Y Avg	+853.60%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	(5.31)
Debt/Equity Ratio Avg TTM	3.56
Debt/Equity Ratio Avg 3Y	0.53
Current VS TTM Avg	-249.43%
Current VS 3Y Avg	-1095.60%
Current VS 5Y Avg	-4814.78%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	0.54%
Earnings Yield Avg TTM	6.28%
Earnings Yield Avg 3Y	6.28%
Current VS TTM Avg	-91.40%
Current VS 3Y Avg	-91.40%
Current VS 5Y Avg	-91.40%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	2.74
Ev/Assets Ratio Avg TTM	7.62
Ev/Assets Ratio Avg 3Y	5.36
Current VS TTM Avg	-64.06%
Current VS 3Y Avg	-48.87%
Current VS 5Y Avg	-38.94%

Ev/Sales Ratio	74.27
Ev/Sales Ratio Avg TTM	95.09
Ev/Sales Ratio Avg 3Y	57.56
Current VS TTM Avg	-21.90%
Current VS 3Y Avg	+29.03%
Current VS 5Y Avg	+19.55%

Current Ratio	0.80
Current Ratio Avg TTM	1.48
Current Ratio Avg 3Y	1.90
Current VS TTM Avg	-45.79%
Current VS 3Y Avg	-57.71%
Current VS 5Y Avg	-80.48%

Quick Ratio	0.80
Quick Ratio Avg TTM	1.48
Quick Ratio Avg 3Y	1.90
Current VS TTM Avg	-45.79%
Current VS 3Y Avg	-57.71%
Current VS 5Y Avg	-80.48%

ROIC	(93.74%)
ROIC Avg 3Y	(134.05%)
ROIC Avg 5Y	(106.86%)
Current VS 3Y Avg	+30.07%
Current VS 5Y Avg	+12.28%
Current VS 10Y Avg	+28.88%

ROA	(65.87%)
ROA Avg TTM	(31.20%)
ROA Avg 3Y	(25.74%)
Current VS TTM Avg	-111.09%
Current VS 3Y Avg	-155.89%
Current VS 5Y Avg	-198.58%

ROE	N/A
ROE Avg TTM	(227.52%)
ROE Avg 3Y	(131.40%)
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Net Profit Margin	(1786.27%)
Net Profit Margin Avg TTM	806.67%
Net Profit Margin Avg 3Y	(1229.25%)
Current VS TTM Avg	-321.44%
Current VS 3Y Avg	-45.31%
Current VS 5Y Avg	-165.18%

Gross Profit Margin	45.86%
Gross Pft Margin Avg TTM	100.00%
Gross Pft Margin Avg 3Y	100.00%
Current VS TTM Avg	-54.14%
Current VS 3Y Avg	-54.14%
Current VS 5Y Avg	-13.68%

Tax Rate	0.00%
Tax Rate Avg 3Y	(55.00%)
Tax Rate Avg 5Y	(41.25%)
Current VS 3Y Avg	+100.00%
Current VS 5Y Avg	+100.00%
Current VS 10Y Avg	+100.00%